Katherine Glaser, MD
MOHS-Micrographic Surgery · Hannibal, MONPI 1497100713
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 67.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $6,205 and has fallen 90.2% since, to $610 in 2025.
Across 43 payments — averaging $233.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Galderma Laboratories, L.p.$515
- Dermavant Sciences, Inc.$469
- Regeneron Healthcare Solutions, Inc.$260
- Davol Inc.$243
- AbbVie$200
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$5,79058%
- Travel & lodging$6827%
- Food & beverage$3,55035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $6,737 |
| Galderma Laboratories, L.p. | 5 | $515 |
| Dermavant Sciences, Inc. | 4 | $469 |
| Regeneron Healthcare Solutions, Inc. | 3 | $260 |
| Davol Inc. | 3 | $243 |
| AbbVie | 3 | $200 |
| Kerecis Limited | 3 | $158 |
| Organogenesis Inc. | 2 | $149 |
| Botanix SB Inc | 1 | $138 |
| Nevro Corp. | 1 | $129 |
| Sanofi | 2 | $129 |
| Amgen | 1 | $128 |
| UCB, Inc. | 1 | $124 |
| Sun Pharmaceutical Industries Inc. | 1 | $124 |
| Boehringer Ingelheim | 1 | $111 |
| AstraZeneca | 1 | $101 |
| Lilly USA, LLC | 2 | $91 |
| Kyowa Kirin, Inc. | 2 | $88 |
| Johnson & Johnson | 1 | $82 |
| Regeneron | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$6,645
- VTAMA$469
- Kerecis Omega3 Marigen$359
- DUPIXENT$223
- SOFDRA$138
- Omnia$129
- Otezla$128
- Bimzelx$124
- BLU-U$124
- ILUMYA$124
- Rinvoq$123
- LIBTAYO$121
- Kerecis Omega3 SurgiClose$120
- Kerecis Omega3 GraftGuide$120
- Phasix Mesh$119
- SPEVIGO$111
- BREZTRI$101
How this compares
$10,021 in reported general payments places this provider in the 75th percentile of 27 mohs-micrographic surgery providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 23 | $148 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Hannibal
- Mark KoryChesterfield$180K
- Ronald WheelandColumbia$109K
- Martha CouncilSaint Louis$38K
- Basia Michalski-McneelySaint Louis$12K
- Lindall PerryColumbia$11K
- Mark CohenKansas City$10K
- Andrew BasnettColumbia$10K
- Sino MehrmalSaint Louis$7K
- Michael SwannSpringfield$6K
- George HruzaChesterfield$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.